Enlonstobart injection

DRUG4 trials

Sponsors

Chongqing University Cancer Hospital, CSPC Megalith Biopharmaceutical Co.,Ltd., CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Conditions

Advanced Hepatocellular Carcinoma (HCC)Head and Neck Squamous Cell CarcinomaLOCALLY ADVANCED CERVICAL CANCERSNon-Small Cell Lung Cancer

Phase 1

Safety and Efficacy of Paclitaxel Liposome Arterial Infusion Combined With Systemic Therapy for Second-Line Treatment of Advanced Liver Cancer

Not yet recruitingNCT07282509

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Advanced Hepatocellular Carcinoma (HCC)

Start: 2025-12-23End: 2029-02-03Target: 116Updated: 2025-12-15

Phase 2

A Single-Arm Exploratory Study of Enlansibumab Sequentially Combined With Concurrent Chemoradiotherapy for Locally Advanced Cervical Cancer

Not yet recruitingNCT06981858

Chongqing University Cancer HospitalLOCALLY ADVANCED CERVICAL CANCERS

Start: 2025-05-15End: 2029-02-01Target: 34Updated: 2025-05-21

SYS6010 Combined With Enlonstobart In Recurrent Or Metastatic Head And Neck Squamous Cell Carcinoma

RecruitingNCT07254585

CSPC Megalith Biopharmaceutical Co.,Ltd.Head and Neck Squamous Cell Carcinoma

Start: 2025-12-18End: 2027-12-31Target: 70Updated: 2026-01-26

Phase 3

SYS6010 Combined With Enlonstobart Versus Immunotherapy+ Platinum-based Chemotherapy for Patients With PD-L1-Positive Locally Advanced or Metastatic NSCLC（SYNSTAR 04）

Not yet recruitingNCT07633873

CSPC Megalith Biopharmaceutical Co.,Ltd.Non-Small Cell Lung Cancer

Start: 2026-06-02End: 2029-05-30Target: 500Updated: 2026-06-11